the respective primary tumor cells, these cell lines can be classified on the basis of MEIS1, HOXA9 and FLT3 gene expression. 4 However, the genes that allowed discrimination of MLL mutant (MLLmu) and MLL wild-type (MLLwt) ALL cells did not permit AML cells with or without MLL mutations to be distinguished. 4 Here, we set out to find genes that would allow one to recognize MLLmu and MLLwt AML cells.
In a first step, we performed gene expression array analysis with pooled RNAs of eight MLLmu and eight MLLwt AML cell lines, respectively, using Affymetrix HG-U133A chips (Santa Clara, CA, USA). We observed that 'brain expressed X-linked 1' (BEX1) was overexpressed 17-fold in the MLLmu panel ( Figure 1 ). It has recently been reported that human BEX1 was expressed in various tissues like the brain, pancreas, testis, kidney, liver, spleen and adrenal gland, but not in peripheral blood leukocytes, lymph nodes and bone marrow. 5 In that study, a probe covering the complete BEX1 coding region had been used.
As BEX1 has a very high-sequence homology to BEX2, we set out to verify these results using a human multiple tissue expression array (BD Biosciences Clontech, Heidelberg, Germany) with BEX1-and BEX2-specific oligonucleotide probes: both genes were strongly expressed in brain-derived tissues. The exclusive expression of BEX1 was seen in the pancreas and testis, and the exclusive expression of BEX2 in the kidney, liver and adrenal gland. Most importantly, however, BEX1 and BEX2 were not expressed in normal cells of the hematopoietic system. Furthermore, reverse transcriptase polymerase chain reaction (RT-PCR) analysis showed that BEX1 was also not expressed in hematopoietic cell lines other than AML (0/32), including cell lines derived from Hodgkin lymphoma, anaplastic large cell lymphoma and ALL. BEX1 was expressed in 82% of the MLLmu AML cell lines (9/11) and in 18% (2/11) of the MLLwt AML cell lines (partly shown in Figure 1a) . The BEX1-positive MLLwt cell lines showed only very weak BEX1 signals, supporting the idea of a positive correlation between MLL gene aberration and high expression levels of BEX1 in AML (Figure 1a and b) . Even MLLmu ALL cell lines tested BEX1 negative (0/5), suggesting that BEX1 might be a true marker for the identification of MLLmu AML cells. With respect to the absence of BEX1 expression in MLLmu ALL cell lines, one might speculate that BEX1 expression depends on the type of MLL rearrangement or on the histological background of the cells.
To test whether the positive correlation of MLL aberration and BEX1 expression, as observed in AML cell lines, also exists in primary cells, we performed quantitative RT-PCR analysis for leukemic blast cells from four patients with AML (2 MLLmu, 2 MLLwt samples). BEX1 expression levels in the two MLLmu samples were similar to those in the MLLmu cell line THP-1, while BEX1 levels in the MLLwt samples were hardly detectable (Figure 2) .
Our results suggest that BEX1 is a candidate gene for the diagnosis of MLLmu AML and raise the question of whether BEX1 plays a role in leukemogenesis. BEX family members interact with neuronal proteins like the p75 neurotrophin receptor and the olfactory marker protein. 6, 7 Both proteins are not expressed in AML-derived cell lines (unpublished own data). Thus, it will be of interest to identify a BEX1 partner in myeloid cells, and to elucidate the possible role of BEX1 for cell signalling processes in MLLmu AML. 
